<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162340</url>
  </required_header>
  <id_info>
    <org_study_id>ICG155-001</org_study_id>
    <nct_id>NCT04162340</nct_id>
  </id_info>
  <brief_title>CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies</brief_title>
  <official_title>CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iCell Gene Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>iCAR Bio, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>iCell Gene Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, interventional, single arm, open label, treatment study to evaluate the
      safety and tolerability of CD4 CAR T cells in patients with relapsed and/or refractory
      multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD4-specific CAR is a chimeric antigen receptor immunotherapy treatment designed to treat
      lymphoma/leukemia expressing CD4 antigen. CD4+ T cell lymphomas are a subset of leukemias and
      lymphomas that are positive for the surface protein CD4. The purpose of this study is to
      evaluate the efficacy and safety of CD4 CAR T cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation phase: CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells with an escalation approach, 2e6 to 5e6 CAR-T cells/kg</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events after CD4 CAR T cells cell infusion</measure>
    <time_frame>2 years particularly the first 28 days after infusion</time_frame>
    <description>Determine the toxicity profile of CD4 CAR T cell therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Incidence of treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Disease Free Survival (DFS) (IMWG criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Progression-Free Survival (IMWG criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CD4 CAR T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation phase: CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells with an escalation approach, 2e6 to 5e6 CAR-T cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD4 CAR T cells</intervention_name>
    <description>CD4 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.</description>
    <arm_group_label>CD4 CAR T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent; Patients volunteer to participate in the research

          -  Diagnosis is mainly based on the World Health Organization (WHO) 2008

          -  Patients have exhausted standard therapeutic options

          -  Systematic usage of immunosuppressive drug or corticosteroid must have been stopped
             for more than 1 weeks

          -  Female must be not pregnant during the study

        Exclusion Criteria:

          -  Patients declining to consent for treatment

          -  Prior solid organ transplantation

          -  Potentially curative therapy including chemotherapy or hematopoietic cell transplant

          -  Any drug used for GVHD must be stopped &gt;1 week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongyu Zhang, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Shenzhen Hospital, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fang Liu, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chengdu Military Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Pinz, MS</last_name>
    <phone>6315386218</phone>
    <email>kevin.pinz@icellgene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yupo Ma, MD/PhD</last_name>
    <phone>7024658132</phone>
    <email>yupo.ma@icellgene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongyu Zhang, MD/PhD</last_name>
      <email>Hongyu.Zhang@pkuszh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chengdu Military General Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fang Liu, MD/PhD</last_name>
      <email>lfyh2006@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD4-specific CAR T</keyword>
  <keyword>T cell leukemia</keyword>
  <keyword>T cell lymphoma</keyword>
  <keyword>CD4CAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

